Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Beautiful Mornin' for Oklahoma's Selexys as it bags $665m Novartis option and venture round

This article was originally published in Scrip

Executive Summary

A Series A financing concurrent with a Big Pharma option to buy your lead drug candidate? The scenario is not as elusive as it may seem, since the US venture Selexys Pharmaceuticals - like other private companies since MPM Capital began managing investment funds for Novartis Pharmaceuticals in 2007 - has achieved both financial milestones in one fell swoop.


Related Content

Finance Watch: Former Alexion Execs Raise $37m To Launch Rare-Disease Focused RallyBio
Novartis Buys Selexys As Competitors Stumble In Sickle Cell


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts